Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueFinished GoodsLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOther Non-Current AssetsPayablesPrepaid AssetsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - Deferred ChargesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Amortization - Deferred ChargesCost of RevenueEBIATGross ProfitMachine, Furnitures, Fixtures & OtherNon-Current ReceivablesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsReceivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Fennec Pharmaceuticals (FENC) Shares Outstanding (2016 - 2025)

Fennec Pharmaceuticals filings provide 16 years of Shares Outstanding readings, the most recent being $34.2 million for Q4 2025.

  • On a quarterly basis, Shares Outstanding rose 24.11% to $34.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $34.2 million, a 24.11% increase, with the full-year FY2025 number at $34.2 million, up 24.11% from a year prior.
  • Shares Outstanding hit $34.2 million in Q4 2025 for Fennec Pharmaceuticals, up from $28.1 million in the prior quarter.
  • In the past five years, Shares Outstanding ranged from a high of $34.2 million in Q4 2025 to a low of $26.0 million in Q1 2021.
  • Median Shares Outstanding over the past 5 years was $26.6 million (2023), compared with a mean of $27.1 million.
  • The widest YoY moves for Shares Outstanding: up 30.69% in 2021, down 0.04% in 2021.
  • Fennec Pharmaceuticals' Shares Outstanding stood at $26.0 million in 2021, then increased by 1.33% to $26.4 million in 2022, then grew by 2.53% to $27.0 million in 2023, then rose by 1.85% to $27.5 million in 2024, then grew by 24.11% to $34.2 million in 2025.
  • The last three reported values for Shares Outstanding were $34.2 million (Q4 2025), $28.1 million (Q3 2025), and $27.7 million (Q2 2025) per Business Quant data.